We are investigating how well T-DXd works in combination with other treatments for patients with HER2-positive oligo-metastatic breast cancer. The study will also look at safety and how it affects cancer markers in the blood.
Health conditions and diseases that the clinical trial is designed to study and treat.
HER2-positive metastatic breast cancer is a type of breast cancer that has spread beyond the breast and lymph nodes to other parts of the body, characterized by the overexpression of the HER2 protein, which can promote the growth of cancer cells.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
